TSCAN THERAPEUTICS, INC. (TCRX) Return on equity 2021–2025
TSCAN THERAPEUTICS, INC. (TCRX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-105.4%FY2025 · since FY2021: -30.2% → -105.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -105.4% | -52.5 pp |
| FY2024 | -52.9% | +6.2 pp |
| FY2023 | -59.1% | +7.5 pp |
| FY2022 | -66.6% | -36.4 pp |
| FY2021 | -30.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice